A5085527689- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Colorectal and Anal Carcinomas
- Circular RNAs in diseases
- Endometriosis Research and Treatment
- Advances in Oncology and Radiotherapy
- Advanced Radiotherapy Techniques
- Chemotherapy-induced cardiotoxicity and mitigation
- Angiogenesis and VEGF in Cancer
- Management of metastatic bone disease
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular Disease and Adiposity
- Cancer-related molecular mechanisms research
- Estrogen and related hormone effects
- Cervical Cancer and HPV Research
- Adipokines, Inflammation, and Metabolic Diseases
- Radiomics and Machine Learning in Medical Imaging
- Venous Thromboembolism Diagnosis and Management
Catharina Ziekenhuis
2023-2025
Radboud University Nijmegen
2023-2025
Leiden University Medical Center
2017-2024
European Organisation for Research and Treatment of Cancer
2021
Health Affairs
2021
United States Department of Veterans Affairs
1966
Albany Medical Center Hospital
1966
PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR) endometrial cancer, comparing pelvic external beam radiotherapy (EBRT) vaginal brachytherapy (VBT). We evaluated long-term outcomes combined the results of pathology review and molecular analysis. 427 HIR cancer were between 2002–2006 to VBT or EBRT. Primary endpoint recurrence (VR). Pathology done in 97.4%, Median follow-up 116 months; 10-year VR 3.4% versus 2.4% vs. EBRT (p = 0.55). Ten-year (PR) more frequent...
Vaginal brachytherapy is currently recommended as adjuvant treatment in patients with high-intermediate risk endometrial cancer to maximize local control and has only mild side effects no or limited impact on quality of life. However, there still considerable overtreatment also some undertreatment, which may be reduced by tailoring the patients' recurrence based molecular tumor characteristics.To compare rates vaginal women cancer, treated after surgery molecular-integrated profile-based...
The molecular classification of endometrial cancer (EC) has proven to have prognostic value and is predictive response adjuvant chemotherapy. Here, we investigate its for external beam radiotherapy (EBRT) vaginal brachytherapy (VBT) in early-stage endometrioid EC (EEC).Data the randomized PORTEC-1 trial (n = 714) comparing pelvic EBRT with no therapy intermediate-risk PORTEC-2 427) VBT high-intermediate-risk were used. Locoregional (including pelvic) recurrence-free survival was compared...
ObjectiveThe Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-4a trial is a randomized for women with high-intermediate risk endometrial cancer (EC), comparing individualized adjuvant treatment based on molecular-integrated profile to standard treatment; vaginal brachytherapy. To evaluate patient acceptability and pathology logistics of determining the profile, pilot phase was included study.MethodsPORTEC-4a ongoing first 50 patients enrolled were phase. Primary endpoints...
BackgroundIn the PORTEC-3 trial, women with high-risk endometrial cancer (HR-EC) were randomised to receive pelvic radiotherapy (RT) or without concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m2 in weeks 1 4 RT, followed by four carboplatin AUC5 paclitaxel 175 mg/m2). Pathology review was required before patient enrolment. The aim this analysis evaluate role central pathology randomisation.Patients methodsA total 1295 cases underwent confirm HR-EC Netherlands (n = 395) UK...
The PORTEC-4a trial investigates molecular-integrated risk profile guided adjuvant treatment for endometrial cancer. quality assurance programme included a dummy run vaginal brachytherapy prior to site activation, and annual verify protocol adherence. Aims of this study were evaluate adherence.For the run, institutes invited create plan on provided CT-scan with applicator in situ. For assurance, data one randomly selected case. A panel reviewed scored plans according checklist.At 15 out 21...
Radiation therapy techniques have developed from 3-dimensional conformal radiation (3DCRT) to intensity modulated (IMRT), with better sparing of the surrounding normal tissues. The current analysis aimed investigate whether IMRT, compared 3DCRT, resulted in fewer adverse events (AEs) and patient-reported symptoms randomized PORTEC-3 trial for high-risk endometrial cancer.Data on AEs quality life (QoL) were available analysis. Physician-reported graded using Common Terminology Criteria...
Abstract Background Numerous studies have shown that elderly women with endometrial cancer (EC) a higher risk of recurrence and cancer-related death. It is, however, unclear whether aging is causal prognostic factor, or other factors become increasingly common age. We address to this unique multi-method study design using state the art statistical inference techniques on datasets three large randomised trials. Methods Data 1801 participating in PORTEC-1, -2 -3 trials were used for analyses...